The global clinical next-generation sequencing (NGS) data analysis market enjoys a valuation of USD 2.3 Billion in 2023, and it is further projected to expand at a CAGR of 17.4% over the forecasted years. According to a recent study by Future Market Insights, NGS data analysis & sequencing services are leading the market with a share of about 41.8% in the year 2022, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2023 | USD 2.3 Billion |
| Market Value 2033 | USD 13.1 Billion |
| CAGR 2023 to 2033 | 17.4% |
| Market Share of Top 5 Countries | 66.0% |
| Key Market Players | Agilent Technologies, Inc.; Illumina, Inc.; Thermo Fisher Scientific, Inc.; Eurofins Scientific; BGI Group; Qiagen; Roche Diagnostics; DNA Star, Inc.; Bio-Rad Laboratories, Inc.; Congenica Ltd.; Theragen Etex Inc.; PerkinElmer, Inc.; Partek Inc.; Oxford Nanopore Technologies PLC.; Pacific Biosciences of California, Inc.; Golden Helix, Inc.; and BioDatomics. |
In order to determine DNA/RNA sequences for the complete genome or to examine a particular region of interest connected to diseases or biological processes, a breakthrough method called next-generation sequencing is being developed. The market for clinical next-generation sequencing data analysis has expanded because of the demand for comprehensive information on genomic sequences.
The nucleotide sequence of entire genomes or specific portions of DNA or RNA can be ascertained using NGS data analysis tools. Sequence alignment, alignment visualisation, gene prediction, and variation analysis tools are a few of the NGS data analysis tools.
With its extremely high throughput, scalability and speed, next-generation sequencing (NGS) is a massively parallel sequencing technology. The sequencers utilised in the sequencing process are known as next-generation sequencing platforms. The NGS platforms contribute to the vast scale delivery of exceptionally high data quality and accuracy.
Explore FMI!
Book a free demo
The global sales of the market are anticipated to rise at a CAGR of 11.9% between 2014 and 2022, owing to the rising prevalence of various chronic diseases.
The global market holds around 39.2% share of the overall global DNA sequencing market with a value of around USD 5.8 Billion, in 2022.
One of the key factors propelling growth of the market in the coming years is the increasing number of life sciences companies. With the expansion of the life sciences industry, numerous small and medium-sized companies are entering the market with novel product offerings and more complex technology to set themselves apart from competitors. Companies conduct extensive research in order to provide novel products.
Owing to the above-mentioned factors, the global market is expected to grow at a prominent pace, and reach a valuation of around USD 13.1 billion during the year 2033.
Technological advances in genomic-based bioinformatics tools are providing many opportunities for market growth. A sizable amount of genetic data is now accessible on web-based bioinformatics platforms because of recent advancements in bioinformatics research and technologies.
Research analysts or data scientists can now compare and assess the quality of their sequencing run, assess in-line control validation, assign sequences to known regions, and characterise other sequences that reflect certain immune receptor clones.
One can infer information about unique immune response traits, their associated current illness scenario, and the consequences of therapeutic antigen presentation by understanding the abundance of particular clones and how they fluctuate in relation to treatment response and disease progression.
Performing tests on relatively tiny samples allows for efficient analysis from easily available material without the need for extra sampling, which is another benefit of genomic-based analyses.
For instance, Illumina released a BaseSpace Informatics Suite in 2014 that enables a lab to follow genetic tests even if it has no genomic computing infrastructure of its own. The suite's extensive software library makes it simple to carry out ordinary data analysis of sequences.
In undeveloped countries, there is less access to modern infrastructure. Therefore, the only alternative for using these technologies to carry out immune repertoire sequencing experiments is outsourcing. Additionally, some outsourcing companies in poor countries are known for offering inferior services.
To be precise, these companies do not actually offer the sequencing service. Instead, they serve as local service providers for companies with operations abroad. They submit samples to companies in other countries for sequencing, and then they get the results. Poor service delivery occurs during the transit and sequence process time due to a number of variables, including inappropriate sample handling, transportation issues, and lengthy wait periods.
Overall, the process is quite costly, takes a long time, and often takes several months to provide the desired outcomes. Therefore, low quality of outsourcing services is likely to limit the overall market growth.
The USA dominates the North American region with a total market share of around 89.1% in 2022 and is expected to continue to experience the same growth throughout the forecast period. The regional dominance is attributed to increasing cancer cases in the region. For instance, according to American Cancer Society, in 2022, 1.9 million new cancer cases were diagnosed and around 609,360-cancer related deaths in the United States were estimated.
Various FDA approvals and rapid technological developments have helped in the growth of this region.
Germany held a market share of around 32.1% in 2022 in the European clinical next-generation sequencing (NGS) data analysis market, owing to increasing collaboration, acquisition, and mergers by the market players in the region. For instance, in April 2022, Illumina and Hannover Medical School signed a contract to evaluate the use of rapid whole-genome sequencing in critically ill kids who are thought to have a hereditary or uncommon condition.
Also, the region is heavily focused on research and developments in the pharmaceutical industry, biotechnological industry, and novel technological developments, which is boosting the market for clinical next-generation sequencing (NGS) data analysis.
China holds a market share of 56.3%, with a market value of USD 107.7 Million in the East Asia clinical next-generation sequencing (NGS) data analysis market in 2022. Increasing prevalence of autism a disorder that causes substantial distress is the main factor stimulating the regional market. For instance, according to NHC Study Team. Prevalence of Autism Spectrum Disorder in China: A Nationwide Multi-center Population-based Study among Children Aged 6 to 12 Years. Neurosci Bull. 2020, out of 142,086 around 363 children were confirmed having autism spectrum disorder.
Disruptive variations in the genome's protein-coding regions can be found with next-generation sequencing (NGS). These NGS techniques changed the search for the ASD gene in conjunction with big cohorts and new statistical techniques. In order to understand the neurobiological effects of altering these ASD-associated genes, functional genetic data, such as gene expression, is greatly benefited from the use of NGS techniques.
NGS data analysis & sequencing services are expected to give high growth at a CAGR of 15.2% between 2023 and 2033. This is because services for NGS data analysis are readily available and reasonably priced. For companies with inadequate infrastructure, this service offers management and interpretation support.
For instance, ArrayGen Technologies provides a broad range of NGS data processing services in the fields of cancer genomics, crop biotechnology, personalised medicine, and disease association research. A comparable selection of NGS data analysis services is offered by ThermoFisher Scientific. The segment growth is attributable to the readily accessible, reasonably priced NGS data analysis services.
Sequencing by synthesis (SBS) is widely adopted with the market share of 42.7% in the global market in 2022. DNA polymerases and dNTPs are employed to replicate (or synthesise) the strand that has to be sequenced in the sequencing by synthesis technique.
De novo sequencing, long-insert paired-end reads for fast sequence assembly, and other applications are provided by SBS technology as well as to short-insert coupled reads for high-resolution genomic studies. Combining short inserts with long reads improves the ability to fully characterise any genome. The segment increase is attributable to SBS's affirmative technology elements.
Medical research in global clinical next-generation sequencing data analysis market is widely used, holding a market share of 39.6% in the global market in 2022. This segment is predicted to increase significantly because of the use of NGS for the study of tumour heterogeneity, the identification of new genes connected to cancer, and the finding of changes related to carcinogenesis.
The Genomic Medicine Service of the National Health Service in the United Kingdom has adopted a sequencing-based method for the clinical investigation of cancer with an unknown cause and the evaluation of potential treatments. Increase in such sequencing-based approaches for various research is anticipated to boost the segment growth.
Academic institutes & research centres hold a market share of 37.7% during the year 2022. Increasing adoption of NGS software platforms the factors attributed for segment growth. Several academic and research organisations now use more NGS software platforms for their projects requiring data interpretation because of falling NGS technology costs.
A further factor that is expected to promote income production in this sector is the gradual increase in the number of qualified employees handling software and computational tools in research institutions. Several institutions provide on-site bioinformatics training programmes and courses with the goal of improving knowledge of various sequencing data analysis options.
Major manufacturers are striving to increase the market reach of both their key products and the solutions they offer to consumers. For instance, today's top manufacturers often offer specialised solutions based on the needs of different end users. Due to the high level of competition in the market, many top competitors are heavily concentrating on various market consolidation operations like merger, acquisition, supply distribution partnerships, and the introduction of new products.
Instances of important developmental strategies used among market participants in the clinical next-generation sequencing (NGS) data analysis market are presented below:
Similarly, the team at Future Market Insights has tracked recent developments related to companies within the clinical next-generation sequencing (NGS) data analysis space. These are available in the full report.
| Attribute | Details |
|---|---|
| Historical Data Available for | 2014 to 2022 |
| Forecast Data | 2023 to 2033 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and the Middle East & Africa |
| Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, The United Kingdom, Germany, Italy, Russia, Spain, France, Benelux, Nordics Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa and South Africa |
| Key Market Segments Covered | Solution and Services, Technology, Application, End User, and Region |
| Key Companies Profiled | Agilent Technologies, Inc.; Illumina, Inc.; Thermo Fisher Scientific, Inc.; Eurofins Scientific; BGI Group; Qiagen; Roche Diagnostics; DNAStar, Inc.; Bio-Rad Laboratories, Inc.; Congenica Ltd.; Theragen Etex Inc.; PerkinElmer, Inc.; Partek Inc.; Oxford Nanopore Technologies PLC.; Pacific Biosciences of California, Inc.; Golden Helix, Inc.; BioDatomics; PierianDx |
| Pricing | Available upon Request |
The global clinical next-generation sequencing (NGS) data analysis market value was USD 2.3 billion in 2022.
In 2022, the revenue generated from sales to academic institutes and research centre was 37.7% of the total.
The China market was valued at USD 107.7 million that is 56.3% of the global market in 2022.
NGS data analysis & sequencing services segment is forecasted to grow at 15.2% CAGR through 2033.
Sequencing by synthesis (SBS) technology is widely adopted and had 42.7% market share in 2022.
Dental 3D Printing Material Market Trends, Growth & Forecast by Material, Product, and Region through 2035
Catheter Market Insights by Product, Indication, End-user, and Region 2025 to 2035
Healthcare Digital Experience Platform Market Trends - Growth & Forecast 2025 to 2035
Human Growth Hormone (HGH) Treatment and Drugs Market Trends - Growth & Forecast 2025 to 2035
Healthcare Interoperability Solutions Market Analysis – Trends & Growth 2025 to 2035
High-end Cellomics Market Analysis - Growth, Trends & Forecast 2025 to 2035
Clinical Next-Generation Sequencing (NGS) Data Analysis Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
